Loading quotes...

Forecast

The analysts' average price target is €256.02 (+6.50%). The median is €252.15 (+4.89%).

Buy	21
Hold	16
Sell	3

News Go to news feed

J&J reports promising Phase 1 results for prostate cancer drug JNJ-6143

Johnson & Johnson said 12 of 16 patients with advanced, measurable prostate tumors treated with investigational oral drug JNJ-6143 achieved a complete or partial response, a 75% objective response rate. The drug disrupts cancer cell function and triggers cell death, addressing a significant unmet need in advanced prostate cancer. Analysts called the data a potential "game-changer" for J&J's oncology franchise, and the company may disclose further development plans, including earlier-line studies, at its Dec. 8 Enterprise Business Review. » More on cnbc.com
Johnson & Johnson raises full-year outlook, stock reacts mixed — analysts remain mostly positive

Johnson & Johnson delivered solid third-quarter results: adjusted earnings per share beat expectations, revenue was about $25.4 billion, and the full-year outlook was raised. The stock initially fell but then turned higher. Twenty of 27 surveyed analysts still recommend buying, although several have slightly lowered their price targets (e.g., RBC, Guggenheim, Wells Fargo). Analysts point to weaker Darzalex pricing outside the U.S., drag from medical‑devices results, and growth coming from older products; Tremfya and Tecvayli beat expectations. » More on deraktionaer.de
Johnson & Johnson posts revenue increase, profit down sharply

Johnson & Johnson raised revenue in the third quarter of 2026 to about $25.4 billion (+6%), driven by a currency-adjusted increase of roughly 8% in the Innovative Medicine segment; MedTech grew moderately by about 2.5%. Reported net profit fell to around $0.2 billion (previous year: $5.2 billion), diluted earnings per share were about $0.09, and adjusted earnings per share were approximately $2.59 (previous year: $2.80). For the full year, the company slightly raised its outlook and now expects revenue of about $101–101.5 billion and adjusted earnings per share of roughly $11.1. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Johnson & Johnson has already paid €3.43 in dividends. The last payout was in September.

Financials

In the last quarter, Johnson & Johnson had revenue of €22.32B and net profit of €184.57M

(EUR)	September 2026	YoY
Revenue	22.32B	8.92%
Gross profit	16.3B	14.31%
Net profit	184.57M	95.81%
EBITDA	5.59B	29.49%

Fundamentals

Metric	Value
Market capitalization	€569.87B
Number of shares	2.41B
52-week high/low	€252.21 - €165.70
Dividend yield	1.91%
Dividends TTM	€4.55
Beta	0.24
P/E ratio	40.00
PEG ratio	-1.09
P/B ratio	7.92
P/S ratio	6.39

Company profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Name	Johnson & Johnson
CEO	Joaquin Duato
Headquarters	New Brunswick, nj USA
Website	investor.jnj.com
Sector	Health Care
Industry	Pharmaceuticals
IPO	06/10/2022
Employees	141,700